A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan shares close up 1.32%
04/26/2024 02:01 PM - Society
Heavy rain advisory issued for 11 cities and counties
04/26/2024 01:37 PM - Society
Taiwan headline news
04/26/2024 11:58 AM - Business
U.S. dollar down in Taipei trading
04/26/2024 10:39 AM - Business
Taiwan shares open higher
04/26/2024 09:19 AM